Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...
Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...
Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...
The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by ...
PARIS (AP) — PARIS (AP) — Sanofi (SNY) on Friday reported third-quarter earnings of $3.09 billion. The company said it had net income of $1.23 per share. Earnings, adjusted for non-recurring costs, ...
Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback